ALSO NOTED: India funds training centers; Memory gains milestone;and much more...

> India is funding clinical research training centers around the country to help spur the country's involvement in drug research. Report

> Memory Pharmaceuticals has received a $2 million milestone for MEM 3454. Release

> VWR International has established a wholly owned subsidiary in Bangalore, India. Release

> EntreMed has begun a Phase II trial of Panzem for ovarian cancer. Release

> Regulators have approved Watson Pharmaceuticals' acquisition of Andrx. Report

> Researchers have grow a miniature liver from stem cells. Report

> Roche's Tamiflu ad campaign featuring penguins (picture) has sparked criticism. Report

And Finally... A new study that concludes a brain abnormality could be behind sudden infant death syndrome points may help researchers develop a new therapy. Article 

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.